Table 1 Characteristics of included studies
Study | Year | Country | Total(n) | Case/Control | Sex male (%) | Age(years) | BMI(kg/m2) | NOS | Combined with hypertension (Yes or NO) | Study design | Detection methods | Outcome indicators |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kato K | 2011 | Japan | 267 | 267 | 81 | 51 ± 14 | 26.3 ± 4.7 | 6 | No | CSS | BN II nephelometer | E |
Yang LT | 2012 | China | 50 | 25/25 | 6 | No | CCS | ELISA | A, D | |||
Yoshihisa A | 2013 | Japan | 50 | 50 | 90 | 59.9 ± 9.9 | 25.0 ± 4.5 | 5 | No | CSS | The particle enhanced immunoturbidimetric assay | D |
Zhang XB(Mild) | 2013 | China | 38 | 15/23 | 100 | 31.93 ± 5.93 | 27.11 ± 4.78 | 7 | No | CCS | BN II nephelometer | A, E |
Zhang XB(Moderate) | 2013 | China | 47 | 24/23 | 100 | 32.46 ± 4.28 | 27.29 ± 2.42 | 7 | No | CCS | BN II nephelometer | A, E |
Zhang XB(Severe) | 2013 | China | 59 | 36/23 | 100 | 32.11 ± 5.80 | 29.69 ± 3.81 | 7 | No | CCS | BN II nephelometer | A, E |
Mutlu M | 2014 | Turkey | 35 | 35 | 40 | 8.74 ± 3.33 | 18.17 ± 3.66 | 7 | No | CSS | ELISA | D |
Xu JM | 2014 | China | 44 | 26/18 | 88.7 | 67.58 ± 9.97 | 23.46 ± 3.21 | 7 | No | CCS | Automatic biochemical analyzer | A |
Zhang XB | 2014 | China | 39 | 39 | 74.4 | 51.2 ± 12.2 | 29.59 ± 5.02 | 8 | No | CCS | BN II nephelometer | D |
Chen Y(Milld) | 2015 | China | 208 | 102/106 | 63.73 | 44.97 ± 10.39 | 27.38 ± 3.68 | 8 | Yes | CCS | Roche C8000 automatic biochemical analyzer | A |
Chen Y(Moderate) | 2015 | China | 259 | 153/106 | 64.71 | 48.46 ± 10.17 | 27.60 ± 3.27 | 8 | Yes | CCS | Roche C8000 automatic biochemical analyzer | A |
Chen Y(Severe) | 2015 | China | 202 | 96/106 | 78.13 | 47.48 ± 10.98 | 29.78 ± 3.53 | 8 | Yes | CCS | Roche C8000 automatic biochemical analyzer | A |
Archontogeorgis K | 2016 | Greece | 84 | 64/20 | 81.25 | 51.78 ± 11.55 | 36.34 ± 13.18 | 9 | No | CCS | ELISA | A |
Hou TT | 2016 | China | 100 | 55/45 | 60 | 57.48 ± 9.97 | 27.6 ± 5.4 | 7 | Yes | CCS | Immunoturbidimetry | A, E |
Jiang Q(Mild) | 2016 | China | 90 | 49/41 | 90 | 43.76 ± 7.80 | 26.56 ± 2.81 | 6 | No | CSS | Automatic biochemical analyzer | A, E |
Jiang Q(Moderate) | 2016 | China | 97 | 56/41 | 91 | 44.32 ± 7.61 | 26.75 ± 3.05 | 6 | No | CSS | Automatic biochemical analyzer | A, E |
Jiang Q(Severe) | 2016 | China | 133 | 92/41 | 99 | 42.42 ± 8.32 | 29.12 ± 4.05 | 6 | No | CSS | Automatic biochemical analyzer | A, E |
Jiang QQ(Mild) | 2016 | China | 199 | 97/102 | 64.95 | 44.53 ± 9.37 | 27.62 ± 3.60 | 6 | Yes | CCS | Automatic biochemical analyzer | A |
Jiang QQ(Moderate) | 2016 | China | 251 | 149/102 | 64.43 | 48.48 ± 9.39 | 27.61 ± 3.25 | 6 | Yes | CCS | Automatic biochemical analyzer | A |
Jiang QQ(Severe) | 2016 | China | 192 | 90/102 | 81.11 | 46.27 ± 9.96 | 29.84 ± 3.57 | 6 | Yes | CCS | Automatic biochemical analyzer | A |
Wei K | 2016 | China | 120 | 90/30 | 46 ± 4.2 | 26.8 ± 3.1 | 6 | No | CSS | Automatic biochemical analyzer | A | |
Mutlu M | 2017 | Turkey | 25 | 25 | 56 | 46.2 ± 9.3 | 30.1 ± 4.4 | 7 | No | CSS | ELISA | D |
Zhang RF | 2017 | China | 95 | 80/15 | 83.15 | 43.51 ± 7.69 | 23.01 ± 2.24 | 7 | No | CCS | Automatic biochemical analyzer | A |
Geovanini GR(Mild) | 2018 | USA | 919 | 449/470 | 48 | 70 ± 9 | 29 ± 5 | 9 | Yes | CSS | BN II nephelometer with a particle-enhanced immunonephelometric assay | A |
Geovanini GR(Moderate) | 2018 | USA | 704 | 234/470 | 53 | 68 ± 9 | 31 ± 5 | 9 | Yes | CSS | BN II nephelometer with a particle-enhanced immunonephelometric assay | A |
Geovanini GR(Severe) | 2018 | USA | 661 | 191/470 | 68 | 68 ± 9 | 32 ± 5 | 9 | Yes | CSS | BN II nephelometer with a particle-enhanced immunonephelometric assay | A |
Voulgaris A | 2018 | Greece | 96 | 64/32 | 84.38 | 51.00 ± 12.20 | 35.90 ± 13.10 | 8 | No | CCS | ELISA | A, E |
Wang SQ | 2018 | China | 264 | 174/90 | 62 | 53.28 ± 11.27 | 26.55 ± 3.92 | 7 | No | CCS | Immunoturbidimetry | A |
Chen DD(Moderate) | 2019 | China | 49 | 34/15 | 100 | 43.32 ± 11.95 | 25.35 ± 2.07 | 7 | No | CCS | NR | A |
Chen DD(Severe) | 2019 | China | 50 | 35/15 | 100 | 42.06 ± 11.75 | 26.12 ± 3.49 | 7 | No | CCS | NR | A |
Chuang LP(Mild) | 2019 | Taiwan | 32 | 24//8 | 87.5 | 43.8 ± 3.0 | 25.5 ± 0.8 | 7 | No | CCS | ELISA | E |
Chuang LP(Moderate) | 2019 | Taiwan | 29 | 21//8 | 90.48 | 41.4 ± 2.2 | 25.3 ± 1.6 | 7 | No | CCS | ELISA | E |
Chuang LP(Severe) | 2019 | Taiwan | 30 | 22//8 | 90.91 | 43.5 ± 2.0 | 26.4 ± 0.6 | 7 | No | CCS | ELISA | E |
Song F(Mild) | 2019 | China | 118 | 64/54 | 78.1 | 42.95 ± 14.03 | 26.22 ± 3.43 | 6 | Yes | CCS | NR | A |
Song F(Moderate) | 2019 | China | 131 | 77/54 | 81.8 | 43.73 ± 12.96 | 27.19 ± 3.64 | 6 | Yes | CCS | NR | A |
Song F(Severe) | 2019 | China | 162 | 108/54 | 91.7 | 40.47 ± 10.90 | 27.33 ± 3.88 | 6 | Yes | CCS | NR | A |
Nowicki M(Mild) | 2020 | Poland | 45 | 45 | 100 | 41.90 ± 11.80 | 32.50 ± 5.40 | 6 | No | CSS | ELISA | B, D, E |
Nowicki M(Severe) | 2020 | Poland | 41 | 41 | 100 | 47.50 ± 8.50 | 36.70 ± 6.10 | 6 | No | CSS | ELISA | B, D, E |
Nowiński A | 2020 | Poland | 240 | 240 | 77 | 56.8 ± 9.9 | 7 | No | CSS | NR | E | |
Duan YY | 2021 | China | 102 | 52/50 | 63.7 | 60.1 ± 11.3 | 27.2 ± 1.9 | 7 | No | CCS | ELISA | A |
Su X | 2021 | China | 932 | 932 | 60.6 | 66(60–96) | 7 | No | CCS | Latex immunoturbidimetric assays | C | |
Li JH | 2022 | China | 1107 | 1107 | 60.7 | 66(60–96) | 8 | No | CCS | NR | C, E | |
Lee S(Mild) | 2024 | USA | 12 | 12 | 83.33 | 43.7 ± 15.8 | 24.9 ± 2.3 | 8 | No | CSS | NR | B, E |
Lee S(Moderate) | 2024 | USA | 12 | 12 | 66.67 | 48.5 ± 11.9 | 25.3 ± 3.4 | 8 | No | CSS | NR | B, E |
Lee S(Severe) | 2024 | USA | 26 | 26 | 84.46 | 47.2 ± 12.3 | 29.2 ± 4.8 | 8 | No | CSS | NR | B, E |